title: Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis.
abstract: BACKGROUND
  Based on clinical representation of disease symptoms multiple sclerosis (MScl) patients can be divided into two major subtypes; relapsing remitting (RR) MScl (85-90%) and primary progressive (PP) MScl (10-15%). Proteomics analysis of cerebrospinal fluid (CSF) has detected a number of proteins that were elevated in MScl patients. Here we specifically aimed to differentiate between the PP and RR subtypes of MScl by comparing CSF proteins.
  
  
  RESULTS
  CSF samples (n = 31) were handled according to the same protocol for quantitative mass spectrometry measurements we reported previously. In the comparison of PP MScl versus RR MScl we observed a number of differentially abundant proteins, such as protein jagged-1 and vitamin D-binding protein. Protein jagged-1 was over three times less abundant in PP MScl compared to RR MScl. Vitamin D-binding protein was only detected in the RR MScl samples. These two proteins were validated by independent techniques (western blot and ELISA) as differentially abundant in the comparison between both MScl types.
  
  
  CONCLUSIONS
  The main finding of this comparative study is the observation that the proteome profiles of CSF in PP and RR MScl patients overlap to a large extent. Still, a number of differences could be observed. Protein jagged-1 is a ligand for multiple Notch receptors and involved in the mediation of Notch signaling. It is suggested in literature that the Notch pathway is involved in the remyelination of MScl lesions. Aberration of normal homeostasis of Vitamin D, of which approximately 90% is bound to vitamin D-binding protein, has been widely implicated in MScl for some years now. Vitamin D directly and indirectly regulates the differentiation, activation of CD4+ T-lymphocytes and can prevent the development of autoimmune processes, and so it may be involved in neuroprotective elements in MScl.
authors.affiliation: Laboratory of Neuro-Oncology, Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
authors.forename: Marcel P
authors.initials: MP
authors.lastname: Stoop
authors.forename: Vaibhav
authors.initials: V
authors.lastname: Singh
authors.forename: Lennard J
authors.initials: LJ
authors.lastname: Dekker
authors.forename: Mark K
authors.initials: MK
authors.lastname: Titulaer
authors.forename: Christoph
authors.initials: C
authors.lastname: Stingl
authors.forename: Peter C
authors.initials: PC
authors.lastname: Burgers
authors.forename: Peter A E
authors.initials: PA
authors.lastname: Sillevis Smitt
authors.forename: Rogier Q
authors.initials: RQ
authors.lastname: Hintzen
authors.forename: Theo M
authors.initials: TM
authors.lastname: Luider
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D015415:Biomarkers / Q000134:cerebrospinal fluid; D016022:Case-Control Studies; D002556:Cerebrospinal Fluid Proteins / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid* / Q000378:metabolism*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid / Q000737:chemistry; D040901:Proteomics; D012008:Recurrence
chemical_list: D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D010446:Peptide Fragments
references.citation: Ann Neurol. 2009 Mar;65(3):239-48
references.pmid: 19334069
references.citation: J Proteome Res. 2009 Mar;8(3):1404-14
references.pmid: 19159215
references.citation: Proteomics. 2008 Apr;8(8):1576-85
references.pmid: 18351689
references.citation: Health Technol Assess. 2002;6(10):1-73
references.pmid: 12022938
references.citation: J Clin Endocrinol Metab. 1986 Oct;63(4):954-9
references.pmid: 3745408
references.citation: J Neurol Sci. 2010 Jan 15;288(1-2):147-50
references.pmid: 19828154
references.citation: J Clin Endocrinol Metab. 1985 Nov;61(5):969-75
references.pmid: 3840175
references.citation: Ann Neurol. 2001 Jul;50(1):121-7
references.pmid: 11456302
references.citation: J Neuroimmunol. 2001 Oct 1;119(2):327-32
references.pmid: 11585636
references.citation: J Immunol. 2009 Mar 15;182(6):3566-72
references.pmid: 19265135
references.citation: Scand J Immunol. 2008 Sep;68(3):261-9
references.pmid: 18510590
references.citation: Cell Mol Neurobiol. 2009 Mar;29(2):203-10
references.pmid: 18807170
references.citation: J Cell Biochem. 2008 Oct 1;105(2):338-43
references.pmid: 18655192
references.citation: Acta Neuropathol. 2007 Feb;113(2):195-203
references.pmid: 17136549
references.citation: PLoS One. 2007 Nov 21;2(11):e1222
references.pmid: 18030350
references.citation: Brain. 2004 Sep;127(Pt 9):1928-41
references.pmid: 15289265
references.citation: Exp Biol Med (Maywood). 2004 Dec;229(11):1136-42
references.pmid: 15564440
references.citation: Eur J Neurol. 2008 Sep;15(9):998-1001
references.pmid: 18637954
references.citation: J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):611-4
references.pmid: 15225848
references.citation: Lancet. 2008 Oct 25;372(9648):1502-17
references.pmid: 18970977
references.citation: Neurosci Lett. 2009 Mar 13;452(2):214-7
references.pmid: 19383442
references.citation: J Chemother. 2001 Jun;13(3):219-34
references.pmid: 11450879
references.citation: Mult Scler. 2009 Dec;15(12):1459-65
references.pmid: 19995843
references.citation: Proteomics. 2005 Jan;5(1):290-6
references.pmid: 15672452
references.citation: Mol Cell Proteomics. 2005 Dec;4(12):2010-21
references.pmid: 16249172
references.citation: Nat Med. 2002 Oct;8(10):1115-21
references.pmid: 12357247
references.citation: Ann Neurol. 2009 Feb;65(2):151-9
references.pmid: 19224535
references.citation: Trends Biotechnol. 2004 Jul;22(7):340-5
references.pmid: 15245906
references.citation: J Neurol. 2008 Oct;255(10):1508-14
references.pmid: 18685917
references.citation: Mult Scler. 2007 Aug;13(7):840-9
references.pmid: 17881397
references.citation: Lancet Neurol. 2007 Oct;6(10):903-12
references.pmid: 17884680
references.citation: J Neuroimmunol. 2006 Oct;179(1-2):108-16
references.pmid: 16934875
references.citation: Nature. 2008 Feb 28;451(7182):1076-81
references.pmid: 18278032
references.citation: Proc Soc Exp Biol Med. 2000 Mar;223(3):230-3
references.pmid: 10719834
references.citation: Annu Rev Neurosci. 2002;25:471-90
references.pmid: 12052917
references.citation: Curr Neurol Neurosci Rep. 2007 May;7(3):239-44
references.pmid: 17488590
references.citation: J Cell Mol Med. 2009 Aug;13(8A):1586-603
references.pmid: 19602050
references.citation: J Neurosci. 2008 Oct 8;28(41):10330-8
references.pmid: 18842892
references.citation: Mult Scler. 2007 Jan;13(1):17-24
references.pmid: 17294607
references.citation: Mol Immunol. 2006 Mar;43(8):1109-15
references.pmid: 16115686